Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B)
Research Program Overview
The Translational Medicine Program at the Center for Autism and the Developing Brain (CADB) recruited participants from 3–17 years of age for a clinical trial to evaluate a medication called oxytocin for use in children and adolescents with autism spectrum disorder (ASD). We wanted to see if this medicine was effective as a supplemental treatment to help improve social functioning in children with ASD.
SOARS-B was sponsored by the National Institute of Health (NIH) and enrolled approximately 300 participants at 6 centers across the United States.
This research was done because there are currently no effective treatments to help improve social functioning in children and adolescents with ASD.